Navigation Links
Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
Date:7/11/2012

JERUSALEM, July 11, 2012 /PRNewswire/ --

Technology to orally administer medications offers far-reaching impact in healthcare industry

Announcing its third patent approval since the beginning of the calendar year, Oramed Pharmaceuticals Inc. (OTCBB:ORMP.OB) (www . oramed . com), a developer of oral drug delivery systems, announced today that its patent, titled  "Methods and Compositions for Oral Administrations of Proteins," was approved by the New Zealand Patent Office. This patent covers a core concept in the Company's technology and is Oramed's second patent to be granted in New Zealand, the first being that of its "Methods in the Oral Administration of Exenatide."  Oramed's portfolio now consists of 4 issued patents and 33 patents pending for its technologies and products.

The current method of administration for peptide-formulated medications is most often via injection. The ability to administer these medications orally offers far-reaching impact on patient compliance and health costs with potential to traverse a broad range of ailments and drug therapies, including diabetes medications, vaccines, and others. Oramed is currently applying its oral delivery technology to its two flagship products - an oral insulin capsule (ORMD-0801) and an oral GLP-1 analog capsule (ORMD-0901) - both of which are indicated for diabetes.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection.&#
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Keryx Biopharmaceuticals to Present at The 7th Annual JMP Securities Healthcare Conference
2. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
3. Access Pharmaceuticals to Report New MuGard Clinical Trial Data This Week at the MASCC/ISOO Symposium in New York City
4. Keryx Biopharmaceuticals Announces Live Webcast of Upcoming Analyst Day
5. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
6. Questcor Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference
7. Questcor Pharmaceuticals Expands Repurchase Program
8. Eutropics Pharmaceuticals Receives U.S. Patent for Novel Diagnostic Method
9. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
10. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
11. Syndax Pharmaceuticals Appoints Arlene Morris as CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... The young Swiss biotech,enterprise AMVAC AG has gained ... most renowned vaccine specialists. Prof. Klein, who was,formerly ... Aventis-Pasteur,Group, will immediately assume directorship of the scientific ... vaccinologist has,access to an outstanding network across one ...
... to Realize ... Critical Path Initiative Goals, MOUNTAIN VIEW, Calif., ... provider of software,strategic consulting, and regulatory services for optimizing clinical ... chief technology officer, has been invited to speak to U.S.,and ...
... PXS; Nasdaq: PXSL) today announced that it had ... Asian and European institutions,and professional investors. The placement ... a series of international Phase III,trials and embarks ... Pharmaxis will issue 12.8 million new fully ...
Cached Biology Technology:Prof. Michel Klein Becomes Chief Scientific Officer at AMVAC 2Pharsight Invited to Present on Winning Strategies for R&D Productivity at New York Pharma Forum on October 15, 2007 2Pharsight Invited to Present on Winning Strategies for R&D Productivity at New York Pharma Forum on October 15, 2007 3Pharmaxis Announces Placement of $50 Million and Share Purchase Plan 2
(Date:12/17/2014)... 2014 Research and Markets ( ... "Global Chemical Sensor Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 One major trend upcoming ... medical sensors in biomedical applications. Chemical sensors help ... correct diagnosis during surgical procedures. The Global Chemical ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ...  report to their offering. One ... in technology. With continuous advances in technology, it ... latest standard that meets the needs and expectations ...
(Date:12/11/2014)... PAUL, Minn. , Dec. 10, 2014 /PRNewswire/ ... wireless physiologic monitoring, has released a new series ... needs of preclinical toxicology researchers. M series, part ... help toxicologists collect the best possible physiologic data ... Adding functional endpoints to toxicology studies ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... (SALT LAKE CITY)Alternating hemiplegia of childhood (AHC) is a ... episodes of paralysis and stiffness, first affecting one side ... and disappear, again and again, and affected children often ... older, children fall progressively behind their peers in both ...
... smog-filled sky or a contaminated river, according to a ... for the prosperous. People living in China,s cities ... more likely to begreen: re-using their plastic grocery bags ... the international journal AMBIO , indicates that the ...
... doesn,t mean making a trip to the local pharmacy for ... the forest to provide a pharmacopeia of medicines to ... But while questions persist about whether such natural remedies are ... examining the phenomenon from a unique perspective, and trying to ...
Cached Biology News:Gene mutations linked to most cases of rare disorder -- Alternating Hemoplegia of Childhood 2Gene mutations linked to most cases of rare disorder -- Alternating Hemoplegia of Childhood 3Pollution can make citizens - both rich and poor - go green 2Health care savings, naturally 2Health care savings, naturally 3
... 5 ml of DETACHaBEAD 19 polyclonal ... CD19 (Pan B). B cells ... and released with DETACHaBEAD CD19 are ... suitable for applications such as culturing ...
This Malachite Green Phosphate Detection Kit...
5-bromo-4-chloro-3-indolyl b -D-galactopyranoside (X-Gal)...
...
Biology Products: